Stories tagged “biotech”, newest first.
Search needs JavaScript. All stories are listed below, newest first.
The protein-degrader developer priced 17,640,000 shares, up from the 14,700,000 in its preliminary prospectus, and was expected to start trading on Nasdaq as LYCA on 23 October 2026.
The cash deal for Phase 1 candidate HCXT-2001 is expected to close in Q4 2026 and to cut Gilead's Q4 GAAP and non-GAAP EPS by about $0.79 to $0.83.
The Shanghai- and Cambridge, Massachusetts-based drugmaker is selling 11.34 million ADSs at $22.04 each, with closing expected on or about 27 October 2026.